Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease
- PMID: 38180638
- DOI: 10.1002/ana.26864
Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625-634.
© 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Similar articles
-
In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.Mol Neurobiol. 2018 Aug;55(8):6449-6462. doi: 10.1007/s12035-017-0848-0. Epub 2018 Jan 6. Mol Neurobiol. 2018. PMID: 29307083
-
Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Epub 2013 Sep 6. Rev Neurol (Paris). 2013. PMID: 24016463 Review.
-
Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.JAMA Neurol. 2015 Oct;72(10):1124-31. doi: 10.1001/jamaneurol.2015.1721. JAMA Neurol. 2015. PMID: 26302353 Free PMC article.
-
Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches.Cell Mol Neurobiol. 2023 Oct;43(7):3115-3136. doi: 10.1007/s10571-023-01365-1. Epub 2023 May 25. Cell Mol Neurobiol. 2023. PMID: 37227619 Free PMC article. Review.
-
Vascular Dysfunction Is Central to Alzheimer's Disease Pathogenesis in APOE e4 Carriers.Int J Mol Sci. 2022 Jun 26;23(13):7106. doi: 10.3390/ijms23137106. Int J Mol Sci. 2022. PMID: 35806110 Free PMC article.
References
-
- Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to ß‐amyloid and increased frequency of type 4 allele in late‐onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977–1981.
-
- Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid ß peptide: isoform specific‐effects and implications for late‐onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:8098–8102.
-
- Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921–923.
-
- Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer's disease: progress to date and the path forward. Neuron 2019;101:820–838.
-
- Choi KY, Lee JJ, Gunasekaran TI, et al. APOE promoter polymorphism‐219T/G is an effect modifier of the influence of APOE epsilon4 on Alzheimer's disease risk in a multiracial sample. J Clin Med 2019;8:1236.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical